Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Fixed dose combination Stories

2009-02-05 13:34:00

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- As biopharmaceutical companies focus on line extensions and new product development opportunities, fixed-dose combination (FDC) products have become an increasingly important segment of the market. In an effort to better understand the development strategies and issues for new FDC products, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Product Commercialization Excellence: Preparation...

2008-12-02 11:51:00

CHAPEL HILL, N.C., Dec. 2 /PRNewswire/ -- New research that delivers a wealth of wide-ranging best practices across major functions such as sales and manufacturing is now available in the Best Practice Database, an online research repository managed by research and consulting firm Best Practices, LLC. To review sample key findings and key topics in these pharmaceutical-focused studies, go to a landing page with links to each of the two new studies at this address:...

2008-10-27 12:00:29

Bristol-Myers Squibb Company has announced positive 96-week data from the Castle study, in which 74% of the 440 patients in the Reyataz/r arm achieved an undetectable viral load, defined as HIV-1 RNA less than 50 copies/ml, compared with 68% of the 443 patients in the lopinavir/r arm. The difference between treatment arms may have been related to the 16% discontinuation rate in the Reyataz/r arm and the 21% discontinuation rate in the lopinavir/r arm, the company said. The international,...

2008-08-08 09:01:34

Ardea Biosciences has presented positive data from its completed Phase IIa proof-of-concept monotherapy study of RDEA806, the company's investigational non-nucleoside reverse transcriptase inhibitor for patients with human immunodeficiency virus, demonstrating robust antiviral activity with a well-tolerated profile. The Phase IIa randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety and tolerability of once- and twice-daily oral dosing...

2008-08-07 15:01:00

MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were effective in treatment-naive patients regardless of baseline viral loads. One of the trials analyzed was a large study comparing treatment with regimens containing EPZICOM versus regimens containing Truvada(R) (tenofovir DF + emtricitabine) in treatment-naive patients with both high and low...

2008-08-07 15:00:12

MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) (tenofovir DF + emtricitabine) as a first-line option for the treatment of HIV. The data were presented today at the 17th International AIDS Conference in Mexico City, Mexico. HEAT is the first large, prospective, long-term, head-to-head trial to evaluate the safety...

2008-08-06 15:00:11

MEXICO CITY, Aug. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) announced today that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV medication abacavir. GSK conducted this review upon learning that the analysis undertaken by the D:A:D cohort had found an unexpected but potential association between highly active antiretroviral therapy (HAART) regimens containing abacavir and an increased...

2008-07-22 18:00:55

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection. The study is designed to assess the non-inferiority of ritonavir-boosted elvitegravir, dosed once daily, compared to raltegravir (Isentress(R)), another integrase inhibitor that is dosed twice daily. The study will...

2008-05-20 09:00:09

Research and Markets (http://www.researchandmarkets.com/reports/c92368) has announced the addition of "The Global Market for Fixed-Dose Combination Drugs for Leading Diseases" to their offering. "The Global Market for Fixed-Dose Combination Drugs for Leading Diseases" analyzes products and applications of fixed-dose combination drugs utilized in the treatment of cardiovascular diseases (hypercholesterolemia and hypertension), diabetes, infectious diseases (bacterial infections, Helicobacter...

2006-07-12 17:35:00

By Susan Heavey and Lisa Richwine WASHINGTON (Reuters) - The first once-a-day AIDS pill that combines three current medicines won U.S. approval on Wednesday, offering patients a more convenient alternative to current multiple drug cocktails. Atripla, which contains Bristol-Myers Squibb Co.'s drug Sustiva and Gilead Inc.'s medicines Viread and Emtriva, is the latest step in making it easier for AIDS patients to keep the human immunodeficiency virus or HIV in check -- a process that once...